Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Exelixis (EXEL) announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Get Instant Summarized Text (Gist) CD74 protein levels can predict immunotherapy response in bowel cancer, regardless of subtype. This discovery could expand treatment eligibility to patients with ...

Researchers at the Francis Crick Institute and Barts Cancer Institute, Queen Mary University of London, have shown that the amount of a protein called CD74 can indicate which people with bowel ...

All 50-74-year-olds in England will now receive a home-testing kit for bowel cancer every ... his local hospital detected a small lesion, found to be early-stage cancer. Keyhole surgery removed ...

Functional pancreatic tumors, although less common than small bowel neuroendocrine tumors (NETs), can have a profound impact on patients’ quality of life. There is a paucity of data on functional ...